
Journal of Molecular and Cellular Cardiology 48 (2010) 322–330

Contents lists available at ScienceDirect

Journal of Molecular and Cellular Cardiology

journal homepage: www.elsevier.com/locate/yjmcc

Review article

**β-Adrenergic receptor signaling in the heart: Role of CaMKII**

Michael Grimm *, Joan Heller Brown

Department of Pharmacology, University of California, San Diego, CA, USA

---

### ARTICLE INFO

Article history:

Received 19 August 2009  
Received in revised form 20 October 2009  
Accepted 23 October 2009  
Available online 31 October 2009  

Keywords:  
CaMKII  
Beta-adrenergic receptor signaling  
Excitation–contraction coupling  
Heart failure  
Hypertrophy  
Apoptosis  
Arrhythmia  

---

### ABSTRACT

The multifunctional Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) targets a number of Ca²⁺ homeostatic proteins and regulates gene transcription. Many of the substrates phosphorylated by CaMKII are also substrates for protein kinase A (PKA), the best known downstream effector of β-adrenergic receptor (β-AR) signaling. While PKA and CaMKII are conventionally considered to transduce signals through separate pathways, there is a body of evidence suggesting that CaMKII is activated in response to β-AR stimulation and that some of the downstream effects of β-AR stimulation are actually mediated by CaMKII. The signaling pathway through which β-AR stimulation activates CaMKII, in parallel with or downstream of PKA, is not well-defined. This review considers the evidence for and mechanisms by which CaMKII is activated in response to β-AR stimulation. In addition the potential role of CaMKII in β-AR regulation of cardiac function is considered. Notably, although many CaMKII targets (e.g., phospholamban or the ryanodine receptor) are central to the regulation of Ca²⁺ handling, and effects of CaMKII on Ca²⁺ handling are detectable, inhibition or gene deletion of CaMKII has relatively little effect on the acute physiological contractile response to β-AR. On the other hand CaMKII expression and activity are increased in heart failure, a pathophysiological condition characterized by chronic stimulation of cardiac β-ARs. Blockade of β-ARs is an accepted therapy for treatment of chronic heart failure although the rationale for its beneficial effects in cardiomyocytes is uncertain. There is growing evidence that inhibition or gene deletion of CaMKII also has a significant beneficial impact on the development of heart failure. The possibility that excessive β-AR stimulation is detrimental because of its effects on CaMKII mediated Ca²⁺ handling disturbances (e.g., ryanodine receptor phosphorylation and diastolic SR Ca²⁺ leak) is an intriguing hypothesis that merits future consideration.

© 2009 Elsevier Ltd. All rights reserved.

---

### Contents

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. Grimm, J.H. Brown / Journal of Molecular and Cellular Cardiology 48 (2010) 322–330

5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. Grimm, J.H. Brown / Journal of Molecular and Cellular Cardiology 48 (2010) 322–330

## 2. Activation of CaMKII by β-AR stimulation

### 2.1. Assessment of CaMKII activity

Essential to the hypothesis that CaMKII mediates the effects of β-AR stimulation is demonstrating that CaMKII is activated in response to β-adrenergic stimulation (Fig. 1). It is possible to measure the enzymatic activity of CaMKII and activation state using specific substrates and addition of its regulators, Ca²⁺ and calmodulin, and this direct approach has in fact been used in some studies [2,15-18]. An alternative is to examine the autophosphorylation of the enzyme at Thr286—several antibodies to this site are commercially available—as this site is phosphorylated following Ca²⁺/CaM binding to and associated with activation of CaMKII [19]. Much of the literature implicating CaMKII in β-AR action, however, has used more indirect readouts, specifically the phosphorylation of putative CaMKII specific target sites on Ca²⁺ regulatory proteins. The two best studied of these are Thr17 on phospholamban (PLN) and Ser2814 or Ser2815 (depending on the species) on the type 2 ryanodine receptor (RyR2). Notably both PLN and RyR2 also have nearby but distinct sites of phosphorylation by PKA (Ser16 on PLN, Ser2809 on RyR2). These latter sites are the accepted known targets of β-AR stimulation and play prominent roles in β-AR regulation of cardiac contraction and relaxation by affecting Ca²⁺ reuptake by and release from the sarcoplasmic reticulum. More surprising is that the PLN (Thr17) and RyR2 (Ser2814) sites mentioned above which have been convincingly demonstrated to be CaMKII specific both *in vitro* [20] and *in vivo* [21] can also be phosphorylated following β-AR stimulation [21,22]. These data implicate CaMKII as a β-AR mediator, as discussed below.

### 2.2. Does the β-AR effect on Ca²⁺ mediate activation of CaMKII?

CaMKII activity responds to the frequency and magnitude of Ca²⁺ signals, both of which are increased by β-AR stimulation of the heart [23]. Inhibition of Ca²⁺ entry via L-type Ca²⁺ channel (LTCC) achieved by lowering Ca²⁺ or using the LTCC blocker nifedipine [9], or depletion of SR Ca²⁺ by ryanodine [24] abolish CaMKII target PLN Thr17 phosphorylation induced by β-AR stimulation. Conversely, activation of LTCC using the agonist Bay K8644 mimics the β-AR-stimulated PLN Thr17 phosphorylation [24]. In contrast, the PKA target PLN Ser16 is directly phosphorylated by PKA, independent of Ca²⁺ entry via LTCC [9,24]. It is not clear whether the normal sympathetic regulation of heart rate and contractility are paralleled by beat-to-beat changes in the activation of CaMKII. CaMKII activation has been modeled based on changes in activity of a FRET based Ca²⁺-calmodulin (CaM) reporter [25]. The authors suggest, based on the kinetics of CaM activation, that phasic activation of CaMKII would occur only in response to high Ca²⁺ levels achieved “locally” in restricted compartments but not “globally” in the cytosol during excitation-contraction coupling [25,26]. The function of such a specialized compartment could be fulfilled by the dyadic cleft where the local Ca²⁺ concentration (and CaM expression) is high as compared to the cytosol, because the LTCC and the RyR are located in close proximity. During β-adrenergic stimulation there are concomitant increases in Ca²⁺ entry via LTCC, SR Ca²⁺ release via RyR, and phosphatase inhibition. Together these would be expected to enhance dyadic cleft Ca²⁺ beyond the very low level maintained during normal beat-to-beat Ca²⁺ transients [26] and this could promote CaMKII activation. The nuclear envelope is another specialized compartment where CaMKII has been suggested to be activated locally by highly elevated Ca²⁺—not directly by β-adrenergic activation but in response to InsP₃ signaling [27].

How dependent is CaMKII activation on local Ca²⁺ levels? As mentioned above, unlike the initial activation of CaMKII by Ca²⁺/CaM, sustained activation occurs by autophosphorylation of CaMKII at Thr287 and this correlates with its downstream effects. Autophosphorylation of CaMKII is provoked by highly elevated Ca²⁺.

Interestingly, the same effect (i.e., autonomous CaMKII activity) can be elicited by ROS-induced oxidation of CaMKII at Met281/282, independent of autophosphorylation [28]. The evidence that Ca²⁺-independent, pro-oxidant conditions can activate CaMKII, and the extensive data showing that stimulation of β-AR can result in ROS production [29-31] suggest that ROS and not Ca²⁺ could link β-adrenergic signaling to CaMKII activity. However, the only study examining this possibility found that autophosphorylation rather than oxidation caused activation of CaMKII in response to β-AR stimulation [28].

### 2.3. Role of PKA in activation of CaMKII

The best-described effect of β-AR stimulation is mediated by the α subunit of the Gs protein, which activates adenylyl cyclase and subsequently increases PKA activity. Phosphorylation of PLN in response to β-AR stimulation in perfused rat hearts has been shown to occur initially through the effects of PKA at Ser16, followed by the effects of CaMKII at Thr17 [9]. Experiments using the PKA inhibitor H-89 in isolated perfused rat hearts provided further evidence that activation of PKA is also required for β-AR mediated phosphorylation of the Thr17 CaMKII site on PLN [11]. The same has been demonstrated for β-AR stimulated phosphorylation of the Ser2815 CaMKII site on RyR2 [10]. The increase in Ser2815 phosphorylation by isoproterenol is CaMKII dependent but probably also dependent on the activation of PKA upstream of CaMKII, because inhibition of PKA and direct activation of PKA inhibited and mimicked the effect of β-AR stimulation, respectively [10]. These data support the concept that PKA is an upstream activator of CaMKII and suggest that CaMKII activation results from PKA-dependent increases in Ca²⁺. There is also a more indirect mechanism by which PKA could stimulate CaMKII activity. Autonomous activity of CaMKII depends on its autophosphorylation at Thr286, which has in turn been suggested to be modulated by the phosphatase PP1 [32,33]. β-AR stimulation suppresses PP1 activity (via PKA-dependent phosphorylation of the PP1 inhibitor I-1 at Thr35.) The physiological relevance of this mechanism was indicated by the demonstration that phosphorylation of the CaMKII targets, RyR Ser2815 and PLN Thr17, in response to the β-AR agonist isoproterenol was reduced in hearts from I-1 KO mice [34].

PKA dependence of CaMKII activation in response to β-AR stimulation does not necessarily mean that targets of PKA and CaMKII are obligatorily phosphorylated in parallel. While CaMKII activation would be responsive to Ca²⁺ elevation and PPI activity, the localized expression of CaM and PP1 (and possibly other phosphatases) would ultimately regulate the kinetics and specificity of CaMKII target phosphorylation. Similarly PKA is found in signaling complexes with different A kinase anchoring proteins (AKAPs), phosphatases and phosphodiesterases, forming local signaling cascades [35,36]. Thus, β-AR stimulation may activate CaMKII via PKA, but phosphorylation of their respective targets could still be regulated relatively independent of each other.

### 2.4. PKA-independent β-adrenergic activation of CaMKII

In a study by Wang et al. [13], chronic β₁-AR stimulation of adult myocytes for 24 h was demonstrated to enhance the contraction amplitude to the same extent as acute β-AR stimulation. The major difference was, however, that acute effects were mediated via PKA whereas chronic effects were mediated via CaMKII (independent of PKA.) Both effects were reversed by a β-blocker or washout, suggesting that continued β-AR activation rather than autonomous CaMKII activity was responsible for the observed effects on contractility. What else might β-AR activation do that could elicit CaMKII mediated responses? It has recently become clear that PKA is not the only downstream effector of β-AR mediated elevation of cAMP.

guanine nucleotide exchange protein directly activated by cAMP (Epac) is a direct target for cAMP [37]. Several papers suggest that Epac can increase CaMKII activity in a PKA-independent manner in isolated adult rat cardiomyocytes, accompanied by enhanced CaMKII target phosphorylation at RyR2 Ser2815 and PLN Thr17 [18, 38–40]. The Epac activator 8-CPT was shown to increase CaMKII autophosphorylation in two recent studies [18, 39] and to increase myofilament Ca²⁺ sensitivity via CaMKII in adult ventricular myocytes [41]. Strikingly, Epac-mediated CaMKII activation showed the exact opposite effect on SR Ca²⁺ release in these studies, i.e., Epac activation either increased [39] or decreased Ca²⁺ transients [18, 41]. The signaling pathway by which Epac activates CaMKII in parallel with and independently of PKA has not been fully delineated. Epac activates the Rap GTPase Rap2B and subsequently a newly described PLC isoform, PLCε [42]. Oestreich et al. [38, 39] recently proposed a pathway by which Epac-mediated PLCε activation stimulates protein kinase C epsilon (PKCε) and hence CaMKII. The authors provide evidence that this pathway mediates β-AR-dependent regulation of SR Ca²⁺ release, in parallel with PKA, in cardiac myocytes. This β-AR and Epac mediated SR Ca²⁺ leak is CaMKII-dependent, but independent of PKA based on experiments in rabbit myocytes using inhibitors of CaMKII or PKA [12, 43].

Catecholamine-induced enhancement of the diastolic SR Ca²⁺ leak can cause ventricular arrhythmia, and Epac has been shown to trigger ventricular arrhythmias through a mechanism dependent on CaMKII activity [44], supporting earlier studies that identified CaMKII as a proarrhythmic signaling molecule in the catecholamine-stimulated heart [45]. PKA-independent activation of CaMKII via Epac may also play a role in the induction of myocardial hypertrophy resulting from chronic stimulation of β-ARs [14, 16, 40]. Knockdown of Epac1 [40] or inhibition of CaMKII suppresses the hypertrophic changes induced by β-AR stimulation in neonatal myocytes [14] and in vivo [16].

### 2.5. Is cAMP required for β-adrenergic CaMKII activation?

Activation of CaMKII through either PKA or through Epac would require cAMP produced by adenylyl cyclase. However, one study that focused on the regulation of the SR Ca²⁺ leak by β-AR stimulation and found that the leak was CaMKII-dependent also reported that it was independent of PKA and cAMP [12]. Direct stimulation of adenylyl cyclase using forskolin was found to stimulate the PKA-dependent Ca²⁺ transient amplitude but not the CaMKII-dependent SR Ca²⁺ leak [12]. That study suggests that an alternative, cAMP-independent pathway mediates β-adrenergic activation of CaMKII. What mechanism can explain cAMP-independent activation of CaMKII in response to β-AR stimulation? One possibility is that the α subunit of Gs, the heterotrimeric G protein that is coupled to the β-AR, directly activates the L-type Ca²⁺ channel independent of cAMP/PKA [46]. The βγ subunits do not appear to function in this way since inhibition of signaling through the βγ subunit of Gs does not prevent activation of CaMKII in response to β-AR stimulation [2]. In addition to the study mentioned above, CaMKII-dependent activation of the fetal gene program in response to chronic ISO was shown to be dependent on activating Ca²⁺ but independent of cAMP and PKA [14].

## 3. CaMKII targets in β-adrenergic signaling

Norepinephrine stimulates postsynaptic β-ARs in the heart resulting in positive chronotropic (heart beats faster), positive inotropic (heart beats stronger), and positive lusitropic (heart relaxes faster) response. Calcium plays a crucial role in regulating these β-adrenergic effects. As described above, Ca²⁺ enters the myocyte via the LTCC, which triggers the release of Ca²⁺ ions from the SR via calcium release channels (RyR). Re-uptake of Ca²⁺ into the SR occurs via SERCA and is regulated by PLN and this, along with extrusion of Ca²⁺ via NCX,

completes the cardiac cycle. Stimulation of cyclic AMP production and activation of PKA facilitates the events described above at several steps. The possible role that CaMKII activation through the β-AR pathway plays in these responses bears consideration, especially because PKA and CaMKII share many intracellular target proteins including the LTCC, RyR and PLN.

### 3.1. Ryanodine receptor

RyR2 is the most abundant RyR isoform in the heart. Studies using mutated full-length RyR2 have indicated Ser2814 as the CaMKII and Ser2808 as the PKA phosphorylation sites, respectively [47, 48]. A second major PKA phosphorylation site at Ser2030 on RyR2 has been suggested to respond to acute β-AR stimulation [49]. However, it appears that only very low amounts of phosphorylated Ser2030 are generated by stimulation with the β-AR agonist isoproterenol in quiescent rat cardiac myocytes [22]. Single-channel experiments and the analysis of the RyR2-S2808A knock-in mouse have indicated Ser2808 as the sole functional PKA phosphorylation site [50]. While it has been suggested by some studies that CaMKII can phosphorylate Ser2808 in vitro [51, 52] and in vivo [53], this finding was not confirmed by others [22, 48]. An early study by Witcher et al. demonstrated CaMKII-dependent phosphorylation of Ser2809 using a tryptic peptide sequence corresponding to residues 2807–2824 [52]. The phosphorylation was also shown using a rabbit antiserum made from a synthetic RyR peptide (residues 2805–2819). It is now clear that the tryptic peptide contained and the antiserum was likely directed against not only Ser2809 but also Ser2815. More than a decade later Wehrens et al. [48] demonstrated that full-length mutant RyR2 channels with an unphosphorylatable CaMKII (S2815A) site could be phosphorylated by PKA but not by CaMKII, implicating Ser2815 as the sole CaMKII site. Interestingly, phosphorylation of wild-type RyR2 channels by exogenous PKA causes dissociation of the regulatory subunit FKBP12.6 from the channel (FKBP12.6 dissociates from Ser2809 phosphorylated RyR2), but this does not occur in response to CaMKII mediated phosphorylation [48]. Taken together, the findings suggest that Ser2809 and Ser2815 are specific sites for PKA and CaMKII, respectively, and that they have different functional consequences. In this regard the fact that stimulation of adult rat ventricular myocytes with isoproterenol can lead not only to the expected phosphorylation of Ser2808 by PKA but also to Ser2815 phosphorylation [22] suggests pleiotropic effects of β-AR signaling on RyR. RyR regulation by PKA and CaMKII has been reviewed recently [54].

### 3.2. Phospholamban

PLN can be directly phosphorylated by either PKA or CaMKII. In vitro assays showed that PKA exclusively catalyzes phosphorylation of PLN Ser16, whereas CaMKII gives exclusive phosphorylation of PLN Thr17 [20]. In the intact heart and in beating papillary muscle preparations, β-AR stimulation results in the phosphorylation of both Ser16 and Thr17 residues of PLN [21, 55, 56]. Recent data demonstrate that it is the β₁-AR subtype that mediates CaMKII activation and PLN Thr17 phosphorylation in response to isoproterenol infusion [57]. Time course experiments show that phosphorylation by PKA occurs within 30 s whereas CaMKII-mediated phosphorylation is seen within 1–3 min [21, 24]. CaMKII-dependent phosphorylation at Thr17—in contrast to PKA-mediated phosphorylation at Ser16—is undetectable in quiescent myocytes stimulated with norepinephrine [32, 58]. In the absence of Ca²⁺ there is Ser16 but no PLN Thr17 phosphorylation in response to β-adrenergic stimulation alone [59], because phosphorylation of Thr17 by CaMKII in response to β-AR stimulation requires influx of Ca²⁺ through the L-type Ca²⁺ channel [9] and release of Ca²⁺ from the SR [24]. It is possible, however, to modulate Thr17 (without affecting Ser16) by using the experimental compound Bay K8644 to

increase LTCC activity [24]. In addition, while PKA-dependent PLN Thr17 phosphorylation has been shown in intact beating hearts [9-11], PKA does not directly phosphorylate Thr17, because SR-targeted inhibition of CaMKII in mouse hearts effectively blocks PLN Thr17 phosphorylation in response to isoproterenol [60,61]. The regulation of CaMKII-dependent PLN phosphorylation and its role under pathophysiological conditions is discussed in a recent review article [62].

### 3.3. Other CaMKII targets

**L-type Ca²⁺ channel.** It is well established that activation of PKA through β-adrenergic stimulation of cAMP production leads to enhanced Ca²⁺ current. The activity of the LTCC is regulated by β-adrenergic stimulation, as well as by Ca²⁺ itself, with a time course similar but not additive to that seen with β-adrenergic stimulation [63]. Ca²⁺-dependent Ica facilitation is due to activation of CaMKII and phosphorylation of the LTCC [64-67]. It has been shown that CaMKII interaction with the pore-forming α₁c subunit of the L-type calcium channel is essential for Ca²⁺-dependent facilitation of the LTCC [68,69]. CaMKII actions at the distal carboxyl-terminus of α₁c may also play a role in β-adrenergic augmentation of cardiac L-type Ca²⁺ current since α₁c (but not phosphorylation of the putative PKA site Ser1928 on α₁c) is required for this effect [70-72]. Recent data suggest that CaMKII also binds to the LTCC β₂a subunit where it phosphorylates the Thr498 site, facilitating Ica [73,74]. Interestingly, there are no data available that directly demonstrate CaMKII-dependent β-adrenergic modulation of Ca²⁺ channel activity. In fact, an earlier study from Anderson et al. demonstrated that CaMKII inhibition did not block Ica activation by β-AR stimulation [65]. Thus more experiments are needed to explore the role of LTCC in CaMKII-dependent β-adrenergic signaling.

**Cardiac myosin binding protein-C (cMyBP-C),** a component of the thick filament, plays a major role as both a structural and regulatory protein in the heart. Phosphorylation of cMyBP-C is important for normal heart function [75-77]. Hartzell and Glass demonstrated phosphorylation of cMyBP-C by purified PKA and CaMKII in vitro [78]. Today three of the serines in cMyBP-C (Ser273, Ser282 and Ser302 in the mouse heart) are known to be substrates for PKA [79,80]. Ser282 can be phosphorylated by CaMKII in addition to PKA and this phosphorylation is thought to be a prerequisite for the phosphorylation of other sites [79]. The functional role of the distinct phosphorylation sites are not known. Cardiac MyBP-C becomes phosphorylated in response to acute β-AR stimulation [81,82]. Contrary to the effect of acute β-adrenergic stimulation, CaMKII-site phosphorylation in cardiac MyBP-C is decreased in patients with heart failure, hypertrophic cardiomyopathy and atrial fibrillation, conditions that are generally associated with increased activities of the sympathetic nervous system and CaMKII [83,84]. It is not known to date why cMyBP-C phosphorylation is paradoxically decreased under conditions of increased PKA and CaMKII signaling.

**Class II histone deacetylases (HDACs)** are known targets of CaMKII in the heart [27,85-89]. CaMKII phosphorylation of class II histone deacetylase 4 (HDAC4), a repressor of the MEF2 transcription factor, results in hypertrophic growth of isolated cardiac myocytes, which can be blocked by a signal-resistant HDAC4 mutant [88]. Moreover, studies using mice with cardiac overexpression of CaMKII (CaMKIIδ TG) show that HDAC4 is phosphorylated and exported out of the nucleus in response to CaMKII [86]. This raises the possibility that CaMKII-mediated phosphorylation of HDAC could be a downstream target of β-AR signaling. However, our own data using CaMKIIδ KO mice [89] and experiments by others using a novel HDAC inhibitor [90] provided evidence against a role for CaMKII or HDAC in β-AR induced hypertrophy. More studies are needed to determine whether HDACs are elements of the β-AR/CaMKII signaling cascade.

---

### 4. Role of CaMKII in β-AR signaling

Acute β-adrenergic activation causes the “fight-or-flight” response that makes the heart beat faster and stronger. Chronic β-adrenergic activation as observed in heart failure results in desensitization of β-adrenergic signaling with a decreased fight-or-flight response (i.e., exercise intolerance) and detrimental changes including hypertrophy, apoptosis and arrhythmias.

#### 4.1. Acute effects of CaMKII on heart rate

The increase in heart rate following β-adrenergic stimulation results from enhancement of the discharge rate of sinoatrial node cells (SANC). The exact mechanism underlying chronotropic effects of β-adrenergic stimulation are only incompletely understood, but potential mechanisms involve stimulation of PKA and phosphorylation of target proteins including the LTCC, RyR, and the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel gene family underlying the pacemaker or “funny” current (If). HCN4 is the most highly expressed isoform of the pore-forming subunits, and β-AR/cAMP directly activates HCN4 [91]. The role of If as a mediator of chronotropic effects of β-AR stimulation has been challenged by experiments showing that pharmacological If blockade [92] or deletion of HCN4 [93] failed to prevent sinus rate acceleration by isoproterenol. In contrast, CaMKII inhibition has been shown to lower the rate of SANC [94] and to block chronotropic responses of β-AR stimulation [95]. CaMKII inhibition is thought to prevent the effects of β-adrenergic stimulation on Ca²⁺ uptake and release from intracellular Ca²⁺ SR stores that are necessary for increasing diastolic depolarization rate in SANC [95]. This proposed mechanism is supported by studies showing that inhibition of the RyR using ryanodine prevents β-adrenergic augmentation of the diastolic depolarization rate [96], even if β-adrenergic effects on Ica current are preserved [97]. However, in another study ryanodine inhibited basal SANC firing rate but failed to block the β-adrenergic rate increase [98]. More information on the β-adrenergic control of cardiac pacemaker function can be found in a recent point/counterpoint discussion and a review article in earlier issues of this journal [99,100].

#### 4.2. Acute effects of CaMKII on Ca²⁺ handling and contractility

As discussed above, CaMKII shares some of the major targets involved in Ca²⁺ regulation with PKA. These targets (LTCC, RyR, and PLN) are important regulators of cardiac excitation-contraction coupling. One would expect that both PKA and CaMKII could modulate contractility in response to β-AR stimulation, but most experimental evidence disproves a role of CaMKII in acute β-adrenergic modulation of contractility [13,16]. The Kranias group showed in PLN-deficient hearts and in transgenic mice expressing T17A or S16A mutant PLN on a PLN null background that phosphorylation of the PKA site Ser16 but not the CaMKII site Thr17 contributes to contractile responses to β-adrenergic agonists [101-103]. This observation is supported by kinetic experiments comparing phosphorylation of PKA and CaMKII target sites on PLN. These studies show a correlation of acute effects of isoproterenol on contractility with cAMP elevation and phosphorylation of the PKA target Ser16, whereas no correlation is found with the phosphorylation of the CaMKII site Thr17 [56].

Although it is generally accepted that PKA targets RyR Ser2808 to allow a greater calcium efflux from the SR [50,104,105], recent studies using a genetically modified mouse with a non-phosphorylatable RyR Ser2808 showed that phosphorylation of Ser2808 does not have a similar role in RyR2 channel function [106,107] or regulation of normal cardiac function by catecholamines [108,109]. It is known that endogenous CaMKIIδ associates directly with RyR2 and modulates RyR2 activity [110] and that phosphorylation of RyR2 by CaMKII

increases channel activity and Ca²⁺ release [52,111,112]. Remarkably, CaMKII-dependent phosphorylation of RyR2 Ser2815 was demonstrated to be responsible for the β-AR induced increase in the channel activity [10], although no data are currently available that show effects of RyR Ser2815 phosphorylation on β-adrenergic regulation of cardiac contractility.

As mentioned above, RyR phosphorylation by CaMKII in the normal heart has as yet no known functional consequences in the response to β-adrenergic stimulation. However, pathophysiological conditions seem to change inotropic regulation. In the study by Wang et al. discussed earlier, chronic exposure to β-AR stimulation was demonstrated to cause a shift from PKA to CaMKII dependence of myocyte contractility [13]. Sustained inotropic responses of isolated myocytes to norepinephrine were largely PKA-independent but sensitive to specific CaMKII inhibitors or adenoviral expression of a dominant-negative CaMKII mutant [13]. Another study [113] found increased activity of CaMKII in mice with genetic disruption of the guanylyl cyclase-A (GC-A) receptor for atrial natriuretic peptide (ANP). In this model, responsiveness to β-AR stimulation was significantly increased and inhibition of CaMKII but not of PKA totally abolished the increased effects of β-adrenergic stimulation on cardiac contractility and Ca²⁺-handling [113].

It has been suggested that CaMKII-dependent PLN Thr17 phosphorylation (like PKA mediated Ser16 phosphorylation) relieves inhibition of SERCA and subsequently more Ca²⁺ is pumped into the SR. This is supported by the finding that transgenic mice expressing a CaMKII inhibitory peptide targeted to the SR (AIP₄-LSR TG) display reduced PLN Thr17 phosphorylation and decreased SR Ca²⁺ uptake [60]. Indeed, the decay of Ca²⁺ transients was also found to be significantly slower in cardiomyocytes from mice expressing another CaMKII inhibitory peptide (AC3-I TG) [114]. The effect of AC3-I was abolished in the absence of PLN (AC3-I × PLN⁻/⁻) [114]. AC3-I myocytes have a reduced SR Ca²⁺ content but a preserved contractile responses to β-AR stimulation [16], whereas AIP₄-LSR TG myocytes show reduced contractility in response to β-AR stimulation without changes in SR Ca²⁺ content [61]. Importantly, the latter study found a significant reduction in PKA target phosphorylation at RyR2809 and PLN Ser16 [61]. Taken together, the studies are in agreement with the observations by the Kranias group that contractile responses to β-AR stimulation do not require CaMKII-dependent phosphorylation of PLN [101-103].

There is an additional and potentially overriding effect of CaMKII on SR Ca²⁺ content mediated via its effect on RyR and its profound consequences on diastolic SR Ca²⁺ leak. Thus, mice with transgenic overexpression of cytoplasmic CaMKII show a reduced SR Ca²⁺ content [86,112] which can be explained by an increased SR Ca²⁺ leak through the RyR. Moreover, increases in the SR Ca²⁺ leak seen with chronic β-adrenergic stimulation or heart failure appear to be due to CaMKII activation as they are clearly rescued by inhibition of CaMKII but not by inhibition of PKA [12,43]. PLN phosphorylation does not seem to modulate the SR Ca²⁺ leak, because Ca²⁺ spark increases by CaMKII can be observed in both WT and PLN-KO myocytes [52,115], consistent with a direct effect of CaMKII on RyR.

Thus, it is not entirely clear if acute CaMKII activity reduces (via RyR) or increases (via PLN) SR Ca²⁺ content or if acute and chronic β-AR stimulation have different consequences on CaMKII-mediated Ca²⁺ handling.

### 4.3. Heart failure

Overexpression of the δc isoform of CaMKII causes heart failure in mice [53,112]. Heart failure is characterized by activation of the sympathetic nervous system, and subsequent stimulation of cardiac β-ARs. CaMKII expression and activity is also increased in human heart failure [116,117] and animal models of heart failure [53]. It is therefore possible that some of the detrimental effects of chronic β₁-AR stimulation are the result of CaMKII activation. Enhanced β₁-AR signaling leads to Ca²⁺ handling disturbances and cell death [118]. There is also evidence that activation of CaMKIIδ triggers cardiomyocyte apoptosis via the primary mitochondrial death pathway [2,17,119]. That the effect of β₁-AR stimulation on cell survival may be in part via CaMKII is suggested by evidence that inhibition of CaMKII protects against apoptosis during excessive β₁-AR stimulation [2,16,120], and that CaMKII inhibition has considerable impact on effects of chronic catecholamine stimulation leading to progression of structural heart disease [2,16,120,121]. These studies suggested that the proapoptotic actions of CaMKII were related to its ability to increase SR Ca²⁺ content because the benefits of CaMKII inhibition were not seen in PLN KO background [114,120]. Further information on the important role of PLN for the apoptotic actions of CaMKII is detailed in a recent review from Couchonnal and Anderson [122]. In addition, enhanced activity of CaMKII causes hyperphosphorylation of the RyR at Ser2815, which leads to an increased diastolic SR Ca²⁺ leak [112,123]. The markedly increased diastolic Ca²⁺ release from the SR could result in increased Ca²⁺ uptake by mitochondria, as the Ca²⁺ leak and mitochondrial Ca²⁺ filling are further enhanced when the SR Ca²⁺ store is repleted (Zhang et al., Circ Res, in revision). A recent screening study using 40 different agents (“bioprobes”) that induce apoptosis in tumor cells suggests that sustained activation of CaMKII has a common role in apoptosis not only in different mammalian cell types but also in response to different apoptotic stimuli [124].

Stimulation of cardiac β-ARs increases oxidative stress, which may have a role in catecholamine-induced heart disease [29-31,125]. ROS-dependent apoptosis [31] and extracellular matrix biosynthesis [29] following β-AR stimulation has been described. Notably, recently published work demonstrated that autonomous CaMKII activity is enhanced by pro-oxidant conditions [28]. However, CaMKII activation and apoptosis that is observed under chronic β-AR stimulation *in vivo* seems to occur independently of oxidative stress but rather depend on CaMKII-dependent increases of intracellular Ca²⁺ as described above [2,28]. Other events that are known to result from chronic CaMKII activation such as afterdepolarizations as triggers of lethal ventricular arrhythmias [126] do, however, appear to be mediated by ROS.

Isoproterenol stimulation was recently demonstrated to induce significantly more arrhythmias in myocytes isolated from CaMKIIδc TG mice, a model in which SR Ca²⁺ leak is markedly increased [127]. Inhibition of CaMKII has also been shown to suppress isoproterenol-induced arrhythmias *in vivo* [45,127]. Further analysis demonstrated that the opening probability of L-type Ca²⁺ channels, which is known to activate early afterdepolarizations (EADs), was significantly higher in myocytes from mice overexpressing a constitutively active form of CaMKIV vs. WT mice [45]. EADs can trigger arrhythmias and a CaMKII inhibitory peptide has been demonstrated to eliminate EADs [45]. Taken together, the data suggest that L-type Ca²⁺ channels and SR Ca²⁺ leak are major contributors to CaMKII-mediated arrhythmias and that this could contribute to the arrythmogenic effect of chronic sympathetic activation.

### 5. Conclusion

CaMKII is a multifunctional signaling molecule that is abundant in the heart and activated by β-AR stimulation. CaMKII targets cytoplasmic proteins important for Ca²⁺ handling such as PLN and the RyR but also transduces Ca²⁺ signals into the nucleus to regulate gene transcription. Chronic inhibition or gene deletion of CaMKII appear to have little effect on basal function of the heart or on acute responses to β-adrenergic stimulation but have a significant beneficial impact on cardiac function under pathological stresses known to be associated with chronic sympathetic activation. Thus, CaMKII has become a promising potential target for heart failure therapy.

References

[1] Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998 Sep 29;98(13):1329–34.

[2] Zhu WZ, Wang SQ, Chakir K, Yang D, Zhang T, Brown JH, et al. Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest 2003 Mar;111(5):617–25.

[3] Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 2001 Feb 13;98(4):1607–12.

[4] Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci U S A 2003 Aug 19;100(17):9986–90.

[5] Tang T, Gao MH, Lai NC, Firth AL, Takahashi T, Guo T, et al. Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling. Circulation 2008 Jan 1;117(1):61–9.

[6] White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A 2000 May 9;97(10):5428–33.

[7] Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001 Mar 6;103(9):1311–6.

[8] Baltas LG, Karczewski P, Bartel S, Krause EG. The endogenous cardiac sarcoplasmic reticulum Ca2+/calmodulin dependent kinase is activated in response to beta-adrenergic stimulation and becomes Ca2+-independent in intact beating hearts. FEBS Lett 1997 Jun 9;409(2):131–6.

[9] Kuschel M, Karczewski P, Hempel P, Schlegel WP, Krause EG, Bartel S. Ser16 prevails over Thr17 phospholamban phosphorylation in the beta-adrenergic regulation of cardiac relaxation. Am J Physiol 1999 May;276(5 Pt 2):H1625–33.

[10] Ferrero P, Said M, Sanchez G, Vittone L, Valverde C, Donoso P, et al. Ca2+-kinase II increases ryanodine binding and Ca2+-induced sarcoplasmic reticulum Ca2+ release kinetics during beta-adrenergic stimulation. J Mol Cell Cardiol 2007 Sep;43(3):281–91.

[11] Said M, Mundina-Weilenmann C, Vittone L, MattiazzI A. The relative relevance of phosphorylation of the Thr(17) residue of phospholamban is different at different levels of beta-adrenergic stimulation. Pflugers Arch 2002 Sep;444(6):801–9.

[12] Curran J, Hinton MJ, Rios E, Bers DM, Shannon TR. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res 2007 Feb 16;100(3):391–8.

[13] Wang W, Zhu W, Wang S, Yang D, Crow MT, Xiao RP, et al. Sustained beta1-adrenergic stimulation modulates cardiac contractility by Ca2+/calmodulin kinase signaling pathway. Circ Res 2004 Oct 15;95(8):798–806.

[14] Sucharov CC, Mariner PD, Nunley KR, Long C, Leinwand I, Bristow MR. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol 2006 Sep;291(3):H1299–308.

[15] Yang D, Zhu WZ, Xiao B, Brochet DX, Chen SR, Lakatta EG, et al. Ca2+/calmodulin kinase II-dependent phosphorylation of ryanodine receptors suppresses Ca2+ sparks and Ca2+ in cardiac myocytes. Circ Res 2007 Feb 16;100(3):399–407.

[16] Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 2005 Apr;11(4):409–17.

[17] Zhu W, Woo AY, Yang D, Cheng H, Crow MT, Xiao RP. Activation of CaMKIIdeltaC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. J Biol Chem 2007 Apr;282(14):10833–9.

[18] Pereira L, Metrich M, Fernandez-Velasco M, Lucas A, Leroy J, Perrier R, et al. The cAMP binding protein Epac modulates Ca2+ sparks by a Ca2+/calmodulin kinase signalling pathway in rat cardiac myocytes. J Physiol 2007 Sep 1;583(Pt 2):685–94.

[19] Hudmon A, Schulman H. Structure-function of the multifunctional Ca2+-/dependent protein kinase II. Biochem J 2002 Jun 15;364(Pt 3):593–611.

[20] Simmerman HK, Collins JH, Theibert JL, Wegener AD, Jones LR. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J Biol Chem 1986 Oct 5;261(28):13333–41.

[21] Wegener AD, Simmerman HK, Lindemann JP, Jones LR. Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. J Biol Chem 1989 Jul 5;264(19):11468–74.

[22] Huke S, Bers DM. Ryanodine receptor phosphorylation at Serine 2030, 2808 and 2814 in rat cardiomyocytes. Biochem Biophys Res Commun 2008 Nov 7;376(1):80–5.

[23] De Koninck P, Schulman H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science 1998 Jan 9;279(5348):227–30.

[24] Bartel S, Vetter D, Schlegel WP, Wallukat G, Krause EG, Karczewski P. Phosphorylation of phospholamban at threonine-17 in the absence and presence of beta-adrenergic stimulation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2000 Dec;32(12):2173–85.

[25] Song Q, Saucerman JJ, Bossuyt J, Bers DM. Differential integration of Ca2+-calmodulin signal in intact ventricular myocytes at low and high affinity Ca2+-calmodulin targets. J Biol Chem 2008 Nov 14;283(46):31531–40.

[26] Saucerman JJ, Bers DM. Calmodulin mediates differential sensitivity of CaMKII and calcineurin to local Ca2+-cardiac myocytes. Biophys J 2008 Nov 15;95(10):4597–612.

[27] Wu X, Zhang T, Bossuyt J, Li X, McKinsey TA, Dedman JR, et al. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest 2006 Mar;116(3):675–82.

[28] Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008 May 2;133(3):462–74.

[29] Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Yao L, et al. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 2005 Jan 1;65(1):230–8.

[30] Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 1982 Nov;60(11):1390–7.

[31] Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K, et al. Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 2003 Feb 7;92(2):136–8.

[32] Huke S, Bers DM. Temporal dissociation of frequency-dependent acceleration of relaxation and protein phosphorylation by CaMKII. J Mol Cell Cardiol 2007 Mar;42(3):590–9.

[33] Bradshaw JM, Kubota Y, Meyer T, Schulman H. An ultrasensitive Ca2+/calmodulin dependent protein kinase II-protein phosphatase 1 switch facilitates specificity in postsynaptic calcium signaling. Proc Natl Acad Sci U S A 2003 Sep 2;100(18):10512–7.

[34] El-Armouche A, Wittkopper K, Degenhardt F, Weinberger F, Didie M, Melnychenko I, et al. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res 2008 Dec 1;80(3):396–406.

[35] Mauban JR, O'Donnell M, Warrier S, Manni S, Bond M. AKAP-scaffolding proteins and regulation of cardiac physiology. Physiology (Bethesda) 2009 Apr;24:78–87.

[36] Carnegie GK, Means CK, Scott JD. A-kinase anchoring proteins: from protein complexes to physiology and disease. IUBMB Life 2009 Apr;61(4):394–406.

[37] de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittehofer A, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998 Dec 3;396(6710):474–7.

[38] Oestreich EA, Malik S, Goonasekera SA, Blaxall BC, Kelley GG, Dirksen RT, et al. Epac and phospholipase Cepsilon regulate Ca2+ release in the heart by activation of protein kinase Cepsilon and calcium-calmodulin kinase II. J Biol Chem 2009 Jan 16;284(3):1514–22.

[39] Oestreich EA, Wang H, Malik S, Kaproth-Joslin KA, Blaxall BC, Kelley GG, et al. Epac-mediated activation of phospholipase C(epsilon) plays a critical role in beta-adrenergic receptor-dependent enhancement of Ca2+ mobilization in cardiac myocytes. J Biol Chem 2007 Feb 23;282(8):5488–95.

[40] Metrich M, Lucas A, Gastineau M, Samuel JL, Heymes C, Morel E, et al. Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res 2008 Apr 25;102(8):959–65.

[41] Cazorla O, Lucas A, Poirier F, Lacampagne A, Lezoualc'h F. The cAMP binding protein Epac regulates cardiac myofilament function. Proc Natl Acad Sci U S A 2009 Aug 18;106(33):14144–9.

[42] Schmidt M, Evellin S, Weernink PA, von Dorp F, Rehmann H, Lomasney JW, et al. A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. Nat Cell Biol 2001 Nov;3(11):1020–4.

[43] Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM. Ca2+/calmodulin dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ Res 2005 Dec 9;97(12):1314–22.

[44] Hothi SS, Gurung IS, Heathcote JC, Zhang Y, Booth SW, Skepper JN, et al. Epac activation, altered calcium homeostasis and ventricular arrhythmogenesis in the murine heart. Pflugers Arch 2008 Nov;457(2):253–70.

[45] Wu Y, Temple J, Zhang R, Dzhura I, Zhang W, Trimble R, et al. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation 2002 Sep 3;106(10):1288–93.

[46] Lader AS, Xiao YF, Ishikawa Y, Cui Y, Vatner DE, Vatner SF, et al. Cardiac Gsalpha overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway. Proc Natl Acad Sci U S A 1998 Aug 4;95(16):9669–74.

[47] Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000 May 12;101(4):365–76.

[48] Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 2004 Apr 2;94(6):e61–70.

[49] Xiao B, Jiang MT, Zhao M, Yang D, Sutherland C, Lai FA, et al. Characterization of a novel PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart failure. Circ Res 2005 Apr 29;96(8):847–55.

[50] Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci U S A 2006 Jan 17;103(3):511–8.

[51] Rodriguez P, Bhogal MS, Colyer J. Stoichiometric phosphorylation of cardiac ryanodine receptor on serine 2809 by calmodulin-dependent kinase II and protein kinase A. J Biol Chem 2003 Oct 3;278(40):38593–600.

[52] Witcher DR, Kovacs RJ, Schulman H, Cefali DC, Jones LR. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem 1991 Jun 15;266(17):11144–52.

[53] Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross Jr J, Bers DM, et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 2003 May 2;92(8):912–9.

[54] Zalk R, Lehnart SE, Marks AR. Modulation of the ryanodine receptor and intracellular calcium. Annu Rev Biochem 2007;76:367–85.

[55] Valverde CA, Mundina-Weilenmann C, Said M, Ferrero P, Vittone L, Salas M, et al. Frequency-dependent acceleration of relaxation in mammalian heart: a property not relying on phospholamban and SERCA2a phosphorylation. J Physiol 2005 Feb 1;562(Pt 3):801–13.

[56] Talosi L, Edes I, Kranias EG. Intracellular mechanisms mediating reversal of beta-adrenergic stimulation in intact beating hearts. Am J Physiol 1993 Mar; 264(3 Pt 2):H791–7.

[57] Yoo B, Lemaire A, Mangmool S, Wolf MJ, Curcio A, Mao L, et al. Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 2009 Oct;297(4):H1377–86.

[58] Hagemann D, Kuschel M, Kuramochi T, Zhu W, Cheng H, Xiao RP. Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes. J Biol Chem 2000 Jul 21;275(29):22532–6.

[59] Mundina-Weilenmann C, Vittone L, Ortale M, de Cingolani GC, Mattiazzi A. Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart. J Biol Chem 1996 Dec 27;271(52):33561–7.

[60] Ji Y, Li B, Reed TD, Lorenz JN, Kaetzel MA, Dedman JR. Targeted inhibition of Ca2+/calmodulin dependent protein kinase II in cardiac longitudinal sarcoplasmic reticulum results in decreased phospholamban phosphorylation at threonine 17. J Biol Chem 2003 Jul 4;278(27):25063–250671.

[61] Ji Y, Zhao W, Li B, Desantiago J, Picht E, Kaetzel MA, et al. Targeted inhibition of sarcoplasmic reticulum CaMKII activity results in alterations of Ca²⁺ homeostasis and cardiac contractility. Am J Physiol Heart Circ Physiol 2006 Feb;290(2): H599–606.

[62] Vittone L, Mundina-Weilenmann C, Mattiazzi A. Phospholamban phosphorylation by CaMKII under pathophysiological conditions. Front Biosci 2008;13:5988–6005.

[63] Gurney AM, Charnet P, Pye JM, Nargeot J. Augmentation of cardiac calcium current by flash photolysis of intracellular caged-Ca²⁺ molecules. Nature 1989 Sep 7;341(6237):65–8.

[64] Yuan W, Bers DM. Ca-dependent facilitation of cardiac Ca current is due to Ca-calmodulin-dependent protein kinase. Am J Physiol 1994 Sep;267(3 Pt 2): H982–93.

[65] Anderson ME, Braun AP, Schulman H, Premack BA. Multifunctional Ca2+/calmodulin dependent protein kinase mediates Ca(2)-induced enhancement of the L-type Ca²⁺ current in rabbit ventricular myocytes. Circ Res 1994 Nov;75(5):854–61.

[66] Xiao RP, Cheng H, Lederer WJ, Suzuki T, Lakatta EG. Dual regulation of Ca2+/ calmodulin dependent kinase II activity by membrane voltage and by calcium influx. Proc Natl Acad Sci U S A 1994 Sep 27;91(20):9659–63.

[67] Dzhura I, Wu Y, Colbran RJ, Balser JR, Anderson ME. Calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels. Nat Cell Biol 2000 Mar;2(3):173–7.

[68] Jahn H, Nastainczyk W, Rohrkasten A, Schneider T, Hofmann F. Site-specific phosphorylation of the purified receptor for calcium-channel blockers by cAMP- and cGMP-dependent protein kinases, protein kinase C, calmodulin-dependent protein kinase II and casein kinase II. Eur J Biochem 1988 Dec 15;178(2):535–42.

[69] Hudmon A, Schulman H, Kim J, Maltez JM, Tsien RW, Pitt GS. CaMKII tethers to L-type Ca²⁺ channels, establishing a local and dedicated integrator of Ca²⁺ signals for facilitation. J Cell Biol 2005 Nov 7;171(3):537–47.

[70] Gao T, Yatani A, Dell'Acqua ML, Sako H, Green SA. cAMP-dependent regulation of cardiac L-type Ca²⁺ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron 1997 Jul;19 (1):185–96.

[71] Ganesan AN, Maack C, Johns DC, Sidor A, O'Rourke B. Beta-adrenergic stimulation of L-type Ca²⁺ channels in cardiac myocytes requires the distal carboxyl terminus of alpha1C but not serine 1928. Circ Res 2006 Feb 3;98(2):e11–8.

[72] Lemke T, Welling A, Christel CJ, Blaich A, Bernhard D, Lenhardt P, et al. Unchanged beta-adrenergic stimulation of cardiac L-type calcium channels in Ca v 1.2 phosphorylation site S1928A mutant mice. J Biol Chem 2008 Dec 12;283(50): 34738–44.

[73] Grueter CE, Colbran RJ, Anderson ME. CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction. J Mol Med 2006 Nov 21.

[74] Grueter CE, Abiria SA, Wu Y, Anderson ME, Colbran RJ. Differential regulated interactions of calcium/calmodulin-dependent protein kinase II with isoforms of voltage-gated calcium channel beta subunits. Biochemistry 2008 Feb 12;47(6): 1760–7.

[75] Nagayama T, Takimoto E, Sadayappan S, Mudd JO, Seidman JG, Robbins J, et al. Control of in vivo left ventricular [correction] contraction/relaxation kinetics by myosin binding protein C: protein kinase A phosphorylation dependent and independent regulation. Circulation 2007 Nov 20;116(21):2399–408.

[76] Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, et al. Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci U S A 2006 Nov 7;103(45):16918–23.

[77] Sadayappan S, Gulick J, Osinska H, Martin LA, Hahn HS, Dorn II GW, et al. Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res 2005 Nov 25;97(11):1156–63.

[78] Hartzell HC, Glass DB. Phosphorylation of purified cardiac muscle C-protein by purified cAMP-dependent and endogenous Ca2+-calmodulin-dependent protein kinases. J Biol Chem 1984 Dec 25;259(24):15587–96.

[79] Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? Embo J 1995 May 1;14(9):1952–60.

[80] Mohamed AS, Dignam JD, Schlender KK. Cardiac myosin-binding protein C (MyBP-C): identification of protein kinase A and protein kinase C phosphorylation sites. Arch Biochem Biophys 1998 Oct 15;358(2):313–9.

[81] Hartzell HC, Titus L. Effects of cholinergic and adrenergic agonists on phosphorylation of a 165,000-dalton myofibrillar protein in intact cardiac muscle. J Biol Chem 1982 Feb 25;257(4):2111–20.

[82] Neumann J, Gupta RC, Jones LR, Bodor GS, Bartel S, Krause EG, et al. Interaction of beta-adrenoceptor and adenosine receptor agonists on phosphorylation. Identification of target proteins in mammalian ventricles. J Mol Cell Cardiol 1995 Aug;27(8):1655–67.

[83] El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S, et al. Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol 2007 Aug;43(2):223–9.

[84] El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U, et al. Molecular determinants of altered Ca²⁺ handling in human chronic atrial fibrillation. Circulation 2006 Aug 15;114(7):670–80.

[85] Bossuyt J, Helmstadter K, Wu X, Clements-Jewery H, Haworth RS, Avkiran M, et al. Ca2+-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res 2008 Mar 28;102(6):695–702.

[86] Zhang T, Kohlhaas M, Backs J, Mishra S, Phillips W, Dybkova N, et al. CaMKII(delta) isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem 2007 Nov 30;282(48):35078–87.

[87] Backs J, Backs T, Bezprozvannaya S, McKinsey TA, Olson EN. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol Cell Biol 2008 May;28(10):3437–45.

[88] Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN, CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 2006 Jul;116(7):1853–64.

[89] Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, et al. Requirement for Ca2+/calmodulin dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest 2009 doi:10.1172/JCI38022.

[90] Kitagawa Y, Tamura Y, Shimizu J, Nakajima-Takenaka C, Taniguchi S, Uesato S, et al. Effects of a novel histone deacetylase inhibitor, N-(2-aminophenyl) benzamide, on a reversible hypertrophy induced by isoproterenol in in situ rat hearts. J Pharmacol Sci 2007 Jun;104(2):167–75.

[91] DiFrancesco D, Tortora P. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 1991 May 9;351(6322):145–7.

[92] Joung B, Tang L, Maruyama M, Han S, Chen Z, Stucky M, et al. Intracellular calcium dynamics and acceleration of sinus rhythm by beta-adrenergic stimulation. Circulation 2009 Feb 17;119(6):788–96.

[93] Herrmann S, Stieber J, Stockl G, Hofmann F, Ludwig A. HCN4 provides a 'depolarization reserve' and is not required for heart rate acceleration in mice. Embo J 2007 Oct 31;26(21):4423–32.

[94] Vinogradova TM, Zhou YY, Bogdanov KY, Yang D, Kuschel M, Cheng H, et al. Sinoatrial node pacemaker activity requires Ca(2)/calmodulin-dependent protein kinase II activation. Circ Res 2000 Oct 27;87(9):760–7.

[95] Wu Y, Gao Z, Chen B, Koval OM, Singh MV, Guan X, et al. Calmodulin kinase II is required for fight or flight sinoatrial node physiology. Proc Natl Acad Sci U S A 2009 Mar 10.

[96] Rigg L, Heath BM, Cui Y, Terrar DA. Localisation and functional significance of ryanodine receptors during beta-adrenoceptor stimulation in the guinea-pig sino-atrial node. Cardiovasc Res 2000 Nov;48(2):254–64.

[97] Vinogradova TM, Bogdanov KY, Lakatta EG. beta-Adrenergic stimulation modulates ryanodine receptor Ca(2) release during diastolic depolarization to accelerate pacemaker activity in rabbit sinoatrial nodal cells. Circ Res 2002 Jan 11;90(1):73–9.

[98] Honjo H, Inada S, Lancaster MK, Yamamoto M, Niwa R, Jones SA, et al. Sarcoplasmic reticulum Ca²⁺ release is not a dominating factor in sinoatrial node pacemaker activity. Circ Res 2003 Feb 21;92(3):e41–4.

[99] Lakatta EG, DiFrancesco D. What keeps us ticking: a funny current, a calcium clock, or both? J Mol Cell Cardiol 2009 Aug;47(2):157–70.

[100] Vinogradova TM, Lakatta EG. Regulation of basal and reserve cardiac pacemaker function by interactions of cAMP-mediated PKA-dependent Ca(2) cycling with surface membrane channels. J Mol Cell Cardiol 2009 Jun 30.

[101] Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994 Sep;75(3): 401–9.

[102] Chu G, Lester JW, Young KB, Luo W, Zhai J, Kranias EG. A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists. J Biol Chem 2000 Dec 8;275(49):38938–43.

[103] Kiss E, Edes I, Sato Y, Luo W, Liggett SB, Kranias EG. beta-Adrenergic regulation of cAMP and protein phosphorylation in phospholamban-knockout mouse hearts. Am J Physiol 1997 Feb;272(2 Pt 2):H785–90.

[104] Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003 Jun 27;113(7): 829–40.

[105] Gomez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 1997 May 2;276(5313):800–6.

[106] Stange M, Xu L, Balshaw D, Yamaguchi N, Meissner G. Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants. J Biol Chem 2003 Dec 19;278 (51):51693–702.

[107] Xiao B, Sutherland C, Walsh MP, Chen SR. Protein kinase A phosphorylation at serine-2808 of the cardiac Ca2+-release channel (ryanodine receptor) does not dissociate 12.6-kDa FK506-binding protein (FKBP12.6). Circ Res 2004 Mar 5;94 (4):487–95.

[108] Benkusky NA, Weber CS, Scherman JA, Farrell EF, Hacker TA, John MC, et al. Intact beta-adrenergic response and unmodified progression toward heart failure in mice with genetic ablation of a major protein kinase A phosphorylation site in the cardiac ryanodine receptor. Circ Res 2007 Oct 12;101(8):819–29.

[109] MacDonnell SM, Garcia-Rivas G, Scherman JA, Kubo H, Chen X, Valdivia H, et al. Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808. Circ Res 2008 Apr 25;102(8): e65–72.

[110] Currie S, Loughrey CM, Craig MA, Smith GL. Calcium/calmodulin-dependent protein kinase IIdelta associates with the ryanodine receptor complex and regulates channel function in rabbit heart. Biochem J 2004 Jan 15;377(Pt 2): 357–66.

[111] Hain J, Onoue H, Mayrleitner M, Fleischer S, Schindler H. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J Biol Chem 1995 Feb 3;270(5):2074–81.

[112] Maier LS, Zhang T, Chen L, DeSantiago J, Brown JH, Bers DM. Transgenic CaMKIIdeltaC overexpression uniquely alters cardiac myocyte Ca²⁺ handling: reduced SR Ca²⁺ load and activated SR Ca²⁺ release. Circ Res 2003 May 2;92(8):904–11.

[113] Yurukova S, Kilic A, Volker K, Leineweber K, Dybkova N, Maier LS, et al. CaMKII-mediated increased lusitropic responses to beta-adrenoreceptor stimulation in ANP-receptor deficient mice. Cardiovasc Res 2007 Mar 1;73(4): 678–88.

[114] Wu Y, Shintani A, Grueter C, Zhang R, Hou Y, Yang J, et al. Suppression of dynamic Ca(2) transient responses to pacing in ventricular myocytes from mice with genetic calmodulin kinase II inhibition. J Mol Cell Cardiol 2006 Feb;40(2): 213–23.

[115] Guo T, Zhang T, Mestril R, Bers DM. Ca2+/calmodulin dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res 2006 Aug 18;99(4):398–406.

[116] Hoch B, Meyer R, Hetzer R, Krause EG, Karczewski P. Identification and expression of delta-isoforms of the multifunctional Ca2+/calmodulin dependent protein kinase in failing and nonfailing human myocardium. Circ Res 1999 Apr 2;84(6): 713–21.

[117] Kirchhefer U, Schmitz W, Scholz H, Neumann J. Activity of cAMP-dependent protein kinase and Ca2+/-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc Res 1999 Apr;42(1):254–61.

[118] Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, et al. Ca2+-and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007 Sep;117(9):2431–44.

[119] Vila-Petroff M, Salas MA, Said M, Valverde CA, Sapia L, Portiansky E, et al. CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. Cardiovasc Res 2007 Mar 1;73(4):689–98.

[120] Yang Y, Zhu WZ, Joiner ML, Zhang R, Oddis CV, Hou Y, et al. Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo. Am J Physiol Heart Circ Physiol 2006 Dec;291(6):H3065–75.

[121] Khoo MS, Li J, Singh MV, Yang Y, Kannankeril P, Wu Y, et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 2006 Sep 26;114(13):1352–9.

[122] Couchonnal LF, Anderson ME. The role of calmodulin kinase II in myocardial physiology and disease. Physiology (Bethesda) 2008 Jun;23:151–9.

[123] Kohlhaas M, Zhang T, Seidler T, Zibrova D, Dybkova N, Steen A, et al. Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ Res 2006 Feb 3;98(2): 235–44.

[124] Olofsson MH, Havelka AM, Brnjic S, Shoshan MC, Linder S. Charting calcium-regulated apoptosis pathways using chemical biology: role of calmodulin kinase II. BMC Chem Biol 2008;8:2.

[125] Zhang GX, Ohmori K, Nagai Y, Fujisawa Y, Nishiyama A, Abe Y, et al. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol 2007 Apr;42(4):804–11.

[126] Xie LH, Chen F, Karagueuzian HS, Weiss JN. Oxidative stress-induced afterdepolarizations and calmodulin kinase II signaling. Circ Res 2009 Jan 2;104(1): 79–86.

[127] Sag CM, Wadsack DP, Khabbazzadeh S, Abesser M, Grefe C, Neumann K, et al. CaMKII contributes to cardiac arrhythmogenesis in heart failure. Circulation: Heart Failure 2009 July 31 doi: 10.1161/CIRCHEARTFAILURE.109.865279.
